Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH
Executive Summary
Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy
You may also be interested in...
Efficacy Data Cushion Tysabri, Burnt By Safety Scare
Biogen Idec weighs in on rumors of malignancies in trials of Tysabri rival cladribine.
Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help
Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug
Good News, Bad News For Novartis' Oral MS Drug, But REMS Could Help
Novartis' fingolimod, which could become the first oral treatment for relapsing-remitting multiple sclerosis, recently beat Biogen Idec's Avonex in a head-to-head Phase III trial. The bad news for Novartis is that a handful of severe safety signals, spotted in Phase II, recurred in this most recent trial of the drug